Celiac

Celiac disease (CD) is a chronic disorder caused by an inflammatory T-cell response to the storage proteins in wheat, rye and barley, which are collectively called “gluten” and characterized by the presence of typical autoantibodies (anti transglutaminase (TTG), anti endomysial, anti-deamidated gliadin peptide) and a range of histological alterations of the small bowel mucosa ranging from increased intra epithelial lymphocytes to total villous atrophy. Genetic (mainly positivity for HLADQ2 and/or DQ8), immunological, and environmental factors (such as microbiota composition, age of gluten introduction, infections etc.) are thought to be necessary for disease expression. Ingestion of gluten by genetically predisposed individuals leads to an uncontrolled T-cell-driven inflammatory response that leads to disruption of the structural and functional integrity of the small bowel mucosa. CD is treated with a gluten-free diet (GFD), which, if appropriately kept, leads to complete resolution of the clinical disease and restoration of the histological abnormalities. CD is not limited to the gastrointestinal tract and some CD patients may present with extraintestinal symptomatology (neurological, dermatological, hepatitis, arthritis etc.) CD is no longer a rare condition, and currently is the most common form of food hypersensitivity in children and adults. CD has significantly changed over the last 3 decades. Disease presentation has significantly changed and now most of the patients are asymptomatic or have atypical presentation. Diagnosis may no longer necessitate small bowel biopsy in selected symptomatic cases with repeated >10 times TTG levels and positive anti endomysial. New modalities to assess diet compliance by measuring gluten immunogenic peptides in urine or stools are now available. New emerging therapies avoiding the need for keeping gluten free diet are in the pipeline. Controversies regarding how strict the diet should be and whether or not to allow oats is an unsolved question.

How we work:

After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days. A 21 day window time frame is allotted for peer-review process wherein multiple experts are contacted. Author proof is generated within 7 working days after the acceptance decision.

Benefits on Publication:

Open Access: Permanent free access to your article upon publication ensures extensive global reach and readership.

Easy Article Sharing: Our open access enables you to share your article directly with colleagues through email and on social media via a single link, permitting third party reuse with appropriate citation in addition to the retention of content copyright by the author.

Global Marketing: Through promotion in a targeted global email announcement or press release, your article will be seen by thousands of the top-most thought-leaders in your field.

Social Media Exposure: Extended reach for your article through links on Twitter accounts provides maximum visibility worldwide.

Reprints: Distribute your work to colleagues and at conferences as we provide hard copy color reprints of your article on order.

Media Contact:
Marcy A
Journal Manager
Journal of Medical and surgical pathology
Email: [email protected]